EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic Interaction Between MALAT1/miR‐30b‐5p/BAFF Axis and Inflammatory Cytokines Underlies Rituximab‐Refractory NMOSD

Meiqun Deng iD, Keyi Zeng, Wei Chen, Jing Chen, Xiaoting Lin, Lei Chen, Yuxin Yao, Hanfei Chen, Aiyu Lin iD

CNS Neuroscience & Therapeutics · 2026-06 · 32 (6)

DOI: 10.1002/cns.70973 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 08.06.2026. Verfasst von Meiqun Deng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Rituximab, MicroRNAs, Neuromyelitis Optica, Cytokines. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Despite achieving complete peripheral B cell deletion after over 6 months of rituximab therapy, a clinically significant minority of neuromyelitis optica spectrum disorder (NMOSD) patients experience breakthrough relapses, yet the underlying mechanism remains unclear. Our study aims to explore the underlying mechanism—the contribution of the MALAT1 /miR‐30b‐5p/BAFF axis activation in monocytes to NMOSD disease attacks and relapses resistant to rituximab therapy.

Methods

To investigate immune dysregulation in NMOSD, we established clinical groups comprising peripheral blood mononuclear cells (PBMCs) and serum from NMOSD patients: onset cases (PBMCs: n = 10; serum: n = 23) and rituximab‐treated cases subdivided into remission ( n = 26) and rituximab‐refractory relapse ( n = 13), along with healthy controls ( n = 15). To profile the MALAT1 /miR‐30b‐5p/BAFF axis and inflammatory mediators, we quantified MALAT1 , miR‐30b‐5p, BAFF, and cytokine levels using qPCR, ELISA, and Western Blot and validated molecular interactions via dual‐luciferase reporter assays. To characterize cellular heterogeneity, single‐cell RNA sequencing (scRNA‐seq) was performed on PBMCs from two rituximab‐refractory relapsed NMOSD patients, two rituximab‐remission NMOSD patients, and two healthy controls. For mechanistic validation, THP‐1 cells were transfected with MALAT1 overexpression constructs or miR‐30b‐5p mimics, followed by functional assessments to determine their roles in monocyte activation and cytokine production.

Results

Significant activation of the MALAT1 /miR‐30b‐5p/BAFF axis was observed in NMOSD patients at disease onset compared to healthy controls. Moreover, this axis correlated with rituximab‐refractory NMOSD, featuring monocyte‐specific MALAT1 upregulation and elevated serum BAFF in rituximab‐refractory relapse patients. In THP‐1 cells, the overexpression of MALAT1 downregulated miR‐30b‐5p, resulting in increased BAFF expression and pro‐inflammatory cytokines secretion (IL‐1β, IL‐8, TNF‐α), while also accelerating cell proliferation. Significantly, transfection with miR‐30b‐5p mimics reversed the MALAT1 ‐driven upregulation of BAFF and pro‐inflammatory cytokines, supporting the MALAT1 /miR‐30b‐5p/BAFF axis as a regulatory circuit underlying inflammatory dysregulation in NMOSD.

Conclusion

We identify the MALAT1 /miR‐30b‐5p axis as a driver of NMOSD pathogenesis and rituximab‐refractory relapse. Upregulation of monocytic MALAT1 suppresses miR‐30b‐5p, leading to increased BAFF and pro‐inflammatory cytokines secretion, thereby promoting inflammatory responses. Targeting this pathway may offer therapeutic potential for relapse prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabMicroRNAsNeuromyelitis OpticaCytokinesRNA, Long NoncodingB-Cell Activating FactorImmunologic FactorsHumansFemaleMaleAdultMiddle Aged

Stichwörter der Autor:innen

MALAT1/miR‐30b‐5p/BAFFmonocyteneuromyelitis optica spectrum disorderrituximab‐refractory

Substanzen

RituximabMicroRNAsMALAT1 long non-coding RNA, humanCytokinesRNA, Long NoncodingB-Cell Activating FactorMIRN30b microRNA, humanTNFSF13B protein, humanImmunologic Factors

Autor:innen und Institutionen

  • Department of Neurology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • The First Clinical College of Fujian Medical University, Fuzhou, Fujian, China.
  • Department of Neurology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Department of Neurology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, China.

ORCID-Profile: Meiqun Deng, Aiyu Lin

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Deng, M., Zeng, K., Chen, W., Chen, J., Lin, X., Chen, L., Yao, Y., Chen, H., & Lin, A. (2026). Synergistic Interaction Between MALAT1/miR‐30b‐5p/BAFF Axis and Inflammatory Cytokines Underlies Rituximab‐Refractory NMOSD. CNS Neuroscience & Therapeutics, 32(6). https://doi.org/10.1002/cns.70973

Vancouver

Deng M, Zeng K, Chen W, Chen J, Lin X, Chen L, et al. Synergistic Interaction Between MALAT1/miR‐30b‐5p/BAFF Axis and Inflammatory Cytokines Underlies Rituximab‐Refractory NMOSD. CNS Neuroscience & Therapeutics. 2026;32(6). doi:10.1002/cns.70973

BibTeX
@article{Deng2026,
  author = {Deng, Meiqun and Zeng, Keyi and Chen, Wei and Chen, Jing and Lin, Xiaoting and Chen, Lei and Yao, Yuxin and Chen, Hanfei and Lin, Aiyu},
  title = {Synergistic Interaction Between MALAT1/miR‐30b‐5p/BAFF Axis and Inflammatory Cytokines Underlies Rituximab‐Refractory NMOSD},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  volume = {32},
  number = {6},
  doi = {10.1002/cns.70973}
}
Kostenlos starten →